PKI-179

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H28N8O3
Molecular Weight	488.5416
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(NC1=CC=NC=C1)NC2=CC=C(C=C2)C3=NC(=NC(=N3)N4[C@H]5CC[C@@H]4COC5)N6CCOCC6

InChI

InChIKey=WXUUCRLKXQMWRY-OYRHEFFESA-N

InChI=1S/C25H28N8O3/c34-25(28-19-7-9-26-10-8-19)27-18-3-1-17(2-4-18)22-29-23(32-11-13-35-14-12-32)31-24(30-22)33-20-5-6-21(33)16-36-15-20/h1-4,7-10,20-21H,5-6,11-16H2,(H2,26,27,28,34)/t20-,21+

HIDE SMILES / InChI

Molecular Formula	C25H28N8O3
Molecular Weight	488.5416
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20797855 | https://www.ncbi.nlm.nih.gov/pubmed/26500112

PKI-179 is an orally efficacious dual PI3K/mTOR inhibitor, possessing antineoplastic activity. The key residues involved in binding of PKI-179 were Ala-805 in PI3Kγ and Ile-2163 in mTOR as they have lost maximum accessible surface area due to binding. By inhibiting the PI3K/mTOR signaling pathway, this agent may inhibit tumor cell proliferation and survival. Evaluation of in vivo efficacy in the nude mouse model bearing MDA-361 human breast cancer tumors showed pronounced tumor growth arrest when dosed above 10 mg/Kg.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphatidylinositol 3-kinase regulatory subunit gamma 1 Target ID: Q92569 Gene ID: 8503.0 Gene Symbol: PIK3R3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26500112	Inhibitor 8504		74.0 nM [IC50]
Serine/threonine-protein kinase mTOR 35 Target ID: P42345 Gene ID: 2475.0 Gene Symbol: MTOR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26500112	Inhibitor 8504		0.42 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Breast cancer 432 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20797855	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches.	2015-11	26500112
PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.	2010-10-01	20797855
Stereoselective synthesis of an active metabolite of the potent PI3 kinase inhibitor PKI-179.	2010-03-05	20112997

Patents

Sample Use Guides

In Vivo Use Guide

in rats: 10 mg/Kg

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:13:47 GMT 2025` Edited by `admin` on `Mon Mar 31 21:13:47 GMT 2025`
Record UNII	CNN7Y60164
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PI 3-K/MTOR INHIBITOR III

Preferred Name

English

PKI-179

Common Name

English

N-(4-(4-(4-MORPHOLINYL)-6-(3-OXA-8-AZABICYCLO(3.2.1)OCT-8-YL)-1,3,5-TRIAZIN-2-YL)PHENYL)-N'-4-PYRIDINYLUREA

Systematic Name

English

UREA, N-(4-(4-(4-MORPHOLINYL)-6-(3-OXA-8-AZABICYCLO(3.2.1)OCT-8-YL)-1,3,5-TRIAZIN-2-YL)PHENYL)-N'-4-PYRIDINYL-

Systematic Name

English

Code System Code Type Description

DRUG BANK

DB13109